Marbofloxacin is a synthetic bactericidal anti-infective, belonging to the family of fluoroquinolones, which acts by inhibiting DNA gyrase.

It is effective in vitro against a wide range of Gram positive bacteria (particularly Staphylococcus) and Gram negative bacteria (Escherichia coli, Pasteurella sp) as well as Mycoplasmas (Mycoplasma bovis).

Streptococcus resistance may appear.
After subcutaneous or intramuscular administration in cattle and pigs at the recommended dose of 2 mg / kg, marbofloxacin is rapidly absorbed, reaching maximum plasma concentrations in less than one hour. Bioavailability is close to 100%. Marbofloxacin is weakly bound to plasma proteins (<10% in pigs and <30% in cattle) and is widely distributed. In most tissues (liver, kidney, skin, lung, bladder, uterus), it reaches concentrations higher than those of plasma.
After intramuscular administration in dairy cows, marbofloxacin reaches maximum concentrations in milk of 1.02 µg / ml (Cmax after the first administration) in 2.5 hours (Tmax after the first administration).
Marbofloxacin is eliminated slowly in pre-ruminant calves (t½ = 5-9 hours) and in pigs (t½ = 8-10 hours), more rapidly in bovines and ruminants (t½ = 4-7 hours) and predominantly in the active form in urine and feces.
After a single intramuscular administration in cows at the recommended dose of 8 mg / kg, the maximum plasma concentration of marbofloxacin (Cmax) is 7.3 µg / ml reached in = 0.78h (Tmax). Plasma protein binding is approximately 30%.
Marbofloxacin is actively excreted in urine and faeces.

Distributed from Mexico